The RSSDI 2020 recommends vaccination in diabetic patients to prevent pneumococcal diseases.1
PCV13 and PPSV23 vaccines are recommended for pneumococcal vaccination.
PCV13 is recommended for adults aged ≥50 years followed by a dose of PPSV23 at least 1 year later (and at least 5 years after their previous PPSV23 dose) depending on the clinical judgment of the physician1
PCV13 must be considered as an important step for vaccinating older diabetic patients who are aged >50 years1
PPSV23 may be offered to immunocompromised patients with diabetes for additional coverage after PCV13
Repeated vaccination with PPSV23 must be avoided to prevent hyporesponsiveness
PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal plain polysaccharide vaccine; RSSDI, Research Society for the Study of Diabetes in India.
FAQs related to different fields
Help protect your adult patients against pneumococcal pneumonia with single-dose administration
Efficacy proven by the CAPiTA study
The ACIP recommends routine use of PCV13 among adults
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.